Fapon Biopharma unveiled its novel anti-CD3/TCR nanobody platform at the 2025 Chinese Biopharmaceutical Association (CBA)-China Annual Meeting, featuring cross-species (human/monkey) binding and enhanced stability for T-cell engager (TCE) development.

The platform has generated multiple TCE candidates including: CD19/BCMA dual-targeting TCE for systemic lupus erythematosus (SLE); Tri-specific TCE with co-stimulatory signals for solid tumours; CD8⁺ T cell-biased TCE for solid tumours.

Vice-president Di Lu highlighted its advantages over conventional antibodies in safety and druggability. Fapon's integrated R&D capabilities span discovery, CMC and early clinical development across oncology and autoimmune diseases.